Rosacea Treatment Guidelines

First-Line Topical Treatments by Phenotype

• The British Journal of Dermatology recommends topical ivermectin 1% cream as first-line therapy for mild inflammatory papules/pustules presentations 1
• The British Journal of Dermatology suggests topical azelaic acid 15% gel/foam as an effective alternative first-line option for inflammatory papules/pustules 1
• Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment showing rapid improvement by week 2 and sustained efficacy for up to 52 weeks for inflammatory papules/pustules 1
• Topical minocycline foam 1.5% is recommended for moderate to severe inflammatory lesions 1
• The British Journal of Dermatology recommends topical α-adrenergics (specifically brimonidine) as first-line therapy for persistent erythema 2
• Topical oxymetazoline is an alternative option for persistent erythema 1

Treatment Approach

• The British Journal of Dermatology suggests a phenotype-based treatment approach, targeting specific signs and symptoms observed by the clinician and those most bothersome to the patient 3, 4
• The traditional subtype-based approach has been replaced by a phenotype-led approach to better address the spectrum of clinical presentations 5, 3
• Combination therapy can be used to treat multiple cutaneous features, with moderate and severe presentations typically requiring combination treatments 6
• If first-line treatment fails, consider either an alternative first-line option or add an additional first-line agent 6

Maintenance Therapy

• The minimum treatment necessary to maintain control should be used, with up to two-thirds of patients relapsing when treatment is discontinued 6, 1
• The approach to maintenance depends on treatment modality and patient desire for ongoing therapy 6

General Skincare Measures

• General skincare underlies the treatment approach to managing cutaneous features, with sun protection (SPF 30+) recommended 6
• Gentle cleansers and moisturizers should be used, with trigger factor avoidance important but limited RCT evidence existing for this approach 6

Special Considerations for Ocular Rosacea

• Lid hygiene and artificial tears are recommended for mild ocular symptoms, with oral doxycycline recommended for moderate to severe cases of ocular rosacea 6, 1
• Ophthalmological referral should be considered for all but the mildest ocular features 3

Common Pitfalls and Caveats

• Insufficient treatment duration can lead to inadequate demonstration of efficacy, with many studies evaluating rosacea treatments lasting less than 8 weeks 6
• Treating based on traditional subtypes rather than phenotypes may lead to inadequate management of the full spectrum of presenting features 5
• Overlooking maintenance therapy can lead to relapse, with up to two-thirds of patients relapsing when treatment is discontinued 1
• Ignoring ocular manifestations can lead to underdiagnosis and undertreatment of ocular rosacea 3

Management of Rosacea Based on Clinical Phenotype and Treatment Response

Treatment Principles

• Encapsulated benzoyl peroxide 5% (E-BPO 5%) offers rapid improvement by week 2 with sustained efficacy up to 52 weeks and excellent tolerability in patients with inflammatory papules/pustules 7
• Oral doxycycline 40 mg modified-release daily has anti-inflammatory activity with reduced gastrointestinal side effects and can be used across all severities of rosacea, including moderate-to-severe inflammatory lesions and ocular rosacea 8, 9
• The British Journal of Dermatology recommends oral beta blockers, such as carvedilol, as a potential treatment option for persistent erythema, although evidence is limited 8, 9

Combination Therapy and Treatment Duration

• Multiple cutaneous features of rosacea can and should be treated simultaneously with more than one agent, with moderate and severe presentations typically requiring combination treatments (topical plus systemic or multiple topicals) 10
• Allow 6-12 weeks for initial therapy before declaring failure, with topical agents requiring shorter duration (6-8 weeks) and oral agents longer (8-12 weeks), as recommended by the British Journal of Dermatology 9
• Without maintenance therapy, up to two-thirds of patients relapse when treatment is discontinued, highlighting the importance of long-term management 9, 10

Essential Adjunctive Measures

• General skincare, including gentle cleansers, moisturizers, and sun protection (SPF 30+), underlies all treatment approaches for rosacea, as emphasized by the British Journal of Dermatology 9
• Trigger factor avoidance, such as spicy foods, alcohol, and extreme temperatures, is essential for managing rosacea, although RCT evidence is limited 9
• Patient education regarding the chronic nature and need for long-term management of rosacea is crucial for successful treatment outcomes, as recommended by the British Journal of Dermatology 9

Treatment of Rosacea

Introduction to Rosacea Treatment

• The Global Rosacea Consensus (ROSCO) panel guidelines do not include topical retinoids in their phenotype-based treatment algorithm for any rosacea feature, as stated by the Global Rosacea Consensus panel 11, 12

First-Line Treatments for Rosacea

• For inflammatory papules/pustules, the American Academy of Dermatology recommends mild disease treatment with topical ivermectin 1% cream, azelaic acid 15% gel/foam, or metronidazole, moderate disease treatment with azelaic acid, ivermectin, or oral doxycycline 40 mg modified-release, and severe disease treatment with ivermectin, oral doxycycline, or oral isotretinoin, as per the 2017 Global Rosacea Consensus guidelines 11
• For persistent erythema, the Global Rosacea Consensus panel recommends topical brimonidine or oxymetazoline, based on evidence from the British Journal of Dermatology 11
• For transient erythema/flushing, the American Academy of Dermatology suggests topical α-adrenergics, oral beta blockers, or pulsed-dye laser, as stated in the British Journal of Dermatology 11

Essential Adjunctive Measures for Rosacea Treatment

• The Global Rosacea Consensus panel guidelines recommend sun protection with SPF 30+ daily, gentle skincare with mild, non-medicated cleansers and moisturizers, based on evidence from the British Journal of Dermatology 11

Treatment Considerations

• The American Academy of Dermatology notes that oral isotretinoin has a role in severe, refractory rosacea, with very low-dose isotretinoin demonstrating 91% clearance or excellent response in mild to moderate papulopustular rosacea, as per the Journal of the American Academy of Dermatology 13
• The Global Rosacea Consensus panel warns against extrapolating acne treatment protocols to rosacea, as rosacea represents a fundamentally different pathophysiology, as stated in the British Journal of Dermatology 11, 12, 14

Treatment of Rosacea with a Phenotype-Based Approach

Introduction to Treatment Options

• The British Journal of Dermatology recommends using pulsed-dye laser or intense pulsed light for severe cases of transient erythema/flushing, and electrodessication, intense pulsed light (IPL), or pulsed-dye laser (PDL) for telangiectasia, as physical modalities are the primary treatment 15
• The British Journal of Dermatology suggests that for phymatous changes, oral doxycycline 40 mg modified-release can be used for clinically inflamed cases, and electrodessication, IPL, or lasers can be used for clinically noninflamed cases 15
• The British Journal of Dermatology advises that for ocular rosacea management, ophthalmological referral should be considered for all but the mildest ocular features, and dermatologists should recognize specific ocular rosacea features such as blepharitis and telangiectasia 15
• The British Journal of Dermatology recommends sun protection with SPF 30+ daily as an essential adjunctive measure for all patients 15

Treatment of Erythematotelangiectatic Rosacea

Therapeutic Approach by Phenotype

• The American Academy of Dermatology recommends brimonidine or oximetazolina topical for persistent erythema, combined with pulsed dye laser (PDL) or intense pulsed light (IPL) for moderate to severe telangiectasias, as first-line treatment, with a warning that both vasoactive agents can cause rebound erythema with continuous use, as reported by the Mayo Clinic Proceedings 16

Adjuvant Essential Measures

• No cited facts are available for this section

Common Pitfalls to Avoid

• No cited facts are available for this section

Management of Rosacea

Introduction to Rosacea Management

• The Global Rosacea Consensus (ROSCO) recommends a transition from subtype-based classification to a phenotype-based approach, which is more effective in handling the diverse spectrum of clinical presentations, according to the British Journal of Dermatology 17

Rosacea Treatment Approach

• The American Academy of Dermatology recommends a phenotype-based treatment approach, where the first-line therapy is chosen based on the specific clinical manifestations present in the patient, with a strength of evidence level of I, according to the British Journal of Dermatology 17

Ocular Rosacea Management

• For mild ocular rosacea symptoms, the American Academy of Ophthalmology recommends eyelid hygiene and artificial tears, with a strength of evidence level of II, according to the British Journal of Dermatology 17
• For moderate to severe ocular rosacea, the American Academy of Ophthalmology recommends doxycycline oral, with a strength of evidence level of I, according to the British Journal of Dermatology 17

Treatment Duration and Evaluation

• The American Academy of Dermatology recommends that topical agents be given 6-8 weeks before declaring treatment failure, with a strength of evidence level of II, according to the British Journal of Dermatology 17
• If treatment is inadequate, the American Academy of Dermatology recommends considering alternative first-line options or adding additional first-line agents, with a strength of evidence level of II, according to the British Journal of Dermatology 17

Maintenance Therapy

• The American Academy of Dermatology recommends using the minimum therapy required to maintain control, as up to two-thirds of patients will relapse when therapy is discontinued, with a strength of evidence level of II, according to the British Journal of Dermatology 17

Evidence‑Based Management of Rosacea with Inflammatory Papules, Pustules, and Pruritus

Phenotype‑Based Treatment Approach

• The standard of care has moved from a subtype‑based model to a phenotype‑based strategy, targeting the specific clinical features (inflammatory lesions, erythema, papules, pustules, pruritus) present in each patient rather than assigning a traditional rosacea subtype. 18, 19

First‑Line Combination Therapy

• In adults with rosacea who exhibit inflammatory papules/pustules and facial itching, initiate combination therapy with topical ivermectin 1 % cream or azelaic acid 15 % gel/foam plus oral doxycycline 40 mg modified‑release once daily, together with basic skincare measures (daily SPF 30+ sunscreen, gentle cleansers, trigger avoidance). This regimen addresses both lesion reduction and pruritus by targeting inflammation and barrier dysfunction. 18

Management of Treatment Failure and Escalation

• If a patient does not achieve an adequate response after 6–8 weeks of topical therapy or 8–12 weeks of oral doxycycline, the next step is to add oral doxycycline to the topical regimen (or switch to an alternative first‑line topical agent) before considering other systemic options. 18

Ocular Involvement Considerations

• For patients presenting with ocular rosacea signs (e.g., burning, foreign‑body sensation, blepharitis), arrange ophthalmologic referral for all but the mildest cases; moderate‑to‑severe ocular involvement should be treated with oral doxycycline in addition to standard skin therapy. 18